Profile data is unavailable for this security.
About the company
Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. The Company is focused on the discovery, development and commercialization of treatments relating to bone marrow/hematopoietic (blood-forming) stem cell (BM/HSC) transplants for blood diseases, including leukemia, lymphoma and bone marrow failure and viral infections. It is developing several distinct and complementary product candidates, as well as a platform technology. To obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, the Company developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. It has developed postnatal human hemogenic endothelial cells (Hu-PHEC cells) to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers. It has developed HEMO-CAR-T, for the potential treatment of acute myeloid leukemia (AML).
- Revenue in GBP (TTM)0.00
- Net income in GBP-6.69m
- Incorporated2013
- Employees17.00
- LocationHemogenyx Pharmaceuticals PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
- Websitehttps://hemogenyx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TheraCryf PLC | 396.00k | -3.14m | 3.54m | 9.00 | -- | 0.9687 | -- | 8.95 | -0.0114 | -0.0114 | 0.0014 | 0.0085 | 0.0858 | -- | 0.9766 | 44,000.00 | -67.93 | -42.50 | -81.69 | -46.66 | -- | -- | -792.17 | -1,482.46 | -- | -- | 0.00 | -- | -10.41 | -- | 22.41 | -- | -- | -- |
| Destiny Pharma PLC | 0.00 | -5.66m | 4.07m | 19.00 | -- | 0.4406 | -- | -- | -0.0624 | -0.0624 | 0.00 | 0.0965 | 0.00 | -- | -- | 0.00 | -60.33 | -54.32 | -67.28 | -59.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 13.02 | -- | 35.39 | -- |
| ImmuPharma PLC | 0.00 | -2.92m | 7.71m | 5.00 | -- | 7.30 | -- | -- | -0.0081 | -0.0081 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -87.27 | -86.13 | -163.24 | -106.39 | -- | -- | -- | -8,634.98 | -- | -8.61 | 0.00 | -- | -- | -- | 23.26 | -- | -- | -- |
| Genflow Biosciences PLC | 0.00 | -1.63m | 7.87m | 5.00 | -- | 9.07 | -- | -- | -0.0056 | -0.0056 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -88.30 | -- | -105.34 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.97 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m | 8.32m | 67.00 | -- | 5.07 | -- | -- | -0.0048 | -0.0048 | 0.00 | 0.0041 | 0.00 | -- | -- | -- | -76.69 | -144.15 | -82.81 | -167.75 | -- | -- | -- | -- | -- | -0.805 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
| Synairgen plc | 0.00 | -8.41m | 9.57m | 36.00 | -- | 0.7557 | -- | -- | -0.0418 | -0.0418 | 0.00 | 0.0629 | 0.00 | -- | -- | 0.00 | -44.55 | -54.01 | -51.06 | -60.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.35 | -- | -26.64 | -- |
| Bivictrix Therapeutics PLC | 0.00 | -2.55m | 10.73m | 12.00 | -- | 3.03 | -- | -- | -0.0351 | -0.0351 | 0.00 | 0.0429 | 0.00 | -- | -- | 0.00 | -57.64 | -- | -65.12 | -- | -- | -- | -- | -- | -- | -- | 0.069 | -- | -- | -- | -1.92 | -- | -- | -- |
| Shield Therapeutics PLC | 13.09m | -33.29m | 12.51m | 73.00 | -- | 0.8324 | -- | 0.9563 | -0.0458 | -0.0458 | 0.0181 | 0.0192 | 0.347 | 3.65 | 1.31 | 179,246.60 | -88.29 | -56.68 | -136.30 | -67.44 | 30.78 | 52.20 | -254.44 | -365.89 | 2.04 | -30.01 | 0.5739 | -- | 137.95 | 1.95 | 33.13 | -- | -2.50 | -- |
| LungLife AI Inc | 35.61k | -4.19m | 13.71m | 15.00 | -- | 0.6033 | -- | 384.93 | -0.1644 | -0.1644 | 0.0014 | 0.2403 | 0.0038 | -- | 0.2831 | 2,373.75 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -6.69m | 17.18m | 17.00 | -- | 5.34 | -- | -- | -0.0061 | -0.0061 | 0.00 | 0.0024 | 0.00 | -- | -- | 0.00 | -101.47 | -82.19 | -112.85 | -95.97 | -- | -- | -- | -- | -- | -28.03 | 0.5144 | -- | -- | -- | -68.14 | -- | 36.68 | -- |
| Skinbiotherapeutics PLC | 161.65k | -2.88m | 18.30m | 11.00 | -- | 4.69 | -- | 113.23 | -0.0165 | -0.0165 | 0.0009 | 0.0192 | 0.0522 | 0.8871 | 0.4181 | 14,695.45 | -93.07 | -52.07 | -115.26 | -57.33 | 62.90 | -- | -1,784.70 | -4,694.37 | 6.48 | -379.78 | 0.0259 | -- | 76.65 | -- | -1.52 | -- | 18.00 | -- |
| OptiBiotix Health PLC | 644.00k | -2.04m | 21.30m | 5.00 | -- | 2.24 | -- | 33.08 | -0.023 | -0.023 | 0.0071 | 0.0973 | 0.0615 | 1.77 | 1.31 | 128,800.00 | -19.46 | 16.82 | -19.90 | 17.52 | 49.69 | 53.03 | -316.61 | 183.49 | 6.62 | -4.87 | 0.00 | 100.14 | 40.92 | 4.60 | -178.82 | -- | -- | -- |
| Oxford Biodynamics PLC | 617.00k | -11.11m | 24.76m | 45.00 | -- | 9.90 | -- | 40.13 | -0.0643 | -0.0643 | 0.0035 | 0.008 | 0.0487 | 1.20 | 0.379 | 13,711.11 | -87.64 | -39.72 | -114.28 | -45.52 | 41.49 | -- | -1,800.32 | -1,324.62 | 0.6156 | -87.72 | 0.7873 | -- | 231.17 | -15.53 | -61.34 | -- | -1.60 | -- |
